Mackenzie Financial’s Puma Biotechnology PBYI Stock Holding History

Mackenzie Financial’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-160,973	Closed	-$966K	–	1668
2025 Q4	$966K	Sell	160,973 -14,237	-8%	-$75.6K	﹤0.01%	1068
2025 Q3	$930K	Sell	175,210 -32,381	-16%	-$137K	﹤0.01%	1086
2025 Q2	$712K	Buy	207,591 +49,878	+32%	+$159K	﹤0.01%	1108
2025 Q1	$467K	Buy	157,713 +79,060	+101%	+$247K	﹤0.01%	1218
2024 Q4	$240K	Buy	+78,653	New	+$229K	﹤0.01%	1480
2022 Q3	–	Sell	-10,090	Closed	-$29K	–	1501
2022 Q2	$29K	Sell	10,090 -2,074	-17%	-$5.16K	﹤0.01%	1421
2022 Q1	$35K	Buy	+12,164	New	+$31.5K	﹤0.01%	1381
2020 Q4	–	Sell	-38,740	Closed	-$391K	–	1081
2020 Q3	$391K	Buy	+38,740	New	+$395K	﹤0.01%	826

Other funds holding PBYI

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Mackenzie Financial's PBYI Position: Q1 2026 in Review

Mackenzie Financial sold out of Puma Biotechnology (PBYI) in Q1 2026, closing a stake of 160,973 shares — an estimated $966K sold.

Mackenzie Financial first reported a position in PBYI in Q3 2020 and held it in 8 quarters. The position peaked at $966K in Q4 2025. 157 funds tracked by Wall St. Rank hold PBYI as of Q1 2026.

Mackenzie Financial reported no remaining Puma Biotechnology position as of Q1 2026 after selling out during the quarter.
Mackenzie Financial sold 160,973 Puma Biotechnology shares in Q1 2026, an estimated $966K.
Mackenzie Financial first reported a position in Puma Biotechnology in Q3 2020 and held it in 8 quarters.
Mackenzie Financial's Puma Biotechnology position peaked at $966K in Q4 2025.
157 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2026.

Based on Mackenzie Financial's 13F filing for Q1 2026, filed 13 May 2026.